Bruker Corporation is actively acquiring PhenomeX in a cash deal valued at $108 million. PhenomeX, a product of Berkeley Lights’ acquisition of IsoPlexis, performs analysis on live biological function. This acquisition will allow Bruker to enter into single-cell research, boosting its spatial biology programs. The PhenomeX systems, which include the Beacon platform and IsoPlexis’ IsoLight and IsoSpark proteomic barcoding systems, will align with Bruker’s analytical and diagnostic solutions. The Beacon Optofluidic system assists in characterizing thousands of single cells in parallel and keeping them healthy for extra profiling. Bruker Corporation expects the deal to close before the end of the year.
To read more, click here.
[Source: Fierce Biotech, August 21st, 2023]